BTK and myeloid sarcoma: Despite the promising safety profiles of second-generation BTK inhibitors observed to date in MS trials, there are several adverse reactions that have previously been associated with first-generation BTK inhibitor administration.4 While not affecting all people taking BTK inhibitors, several adverse reactions are of concern when long-term administration is considered.